Providing insights into the genetic and molecular basis of disease. HTML Image Alison Munro: Facility Manager (left) and Camilla Drake: Research Technician (right) The MRC Institute of Genetics and Molecular Medicine/Cancer Research UK Edinburgh Centre houses cutting edge protein, antibody and transcriptomic microarray facilities for the analysis of complex signalling pathways and secreted factors (e.g. chemokines/cytokines) across multiple pre-clinical and clinical sample types. Our facility brings together industry leading platforms, like the high throughput Quanterix-2470-microarrayer, Innopsys 710 infra-red microarray scanner, Zeptosens RPPA system, and NanoString. The technologies we offer in this facility are Reverse Phase Protein Arrays Forward Phase Antibody Microarrays NanoString Each microarray platform enables rapid and robust quantification of biomarkers at transcriptomic and post-translational pathway levels across multiple sample sets. Study size can be scaled to the needs of the experiment. People Professor Neil Carragher Academic Lead Alison Munro Facility Manager Camilla Drake Research Technician Our facilities are available to all within the University of Edinburgh, and also to external groups through funded collaboration or fee-for-service contract. NanoString Life science tools for translational research and molecular diagnostics Reverse Phase Protein Arrays Rapid and robust quantification of biomarkers at the post-translational pathway level Forward Phase Antibody Microarrays Rapid detection of protein analytes including cytokine and chemokines across multiple samples This article was published on 2024-06-21
HTML Image Alison Munro: Facility Manager (left) and Camilla Drake: Research Technician (right) The MRC Institute of Genetics and Molecular Medicine/Cancer Research UK Edinburgh Centre houses cutting edge protein, antibody and transcriptomic microarray facilities for the analysis of complex signalling pathways and secreted factors (e.g. chemokines/cytokines) across multiple pre-clinical and clinical sample types. Our facility brings together industry leading platforms, like the high throughput Quanterix-2470-microarrayer, Innopsys 710 infra-red microarray scanner, Zeptosens RPPA system, and NanoString. The technologies we offer in this facility are Reverse Phase Protein Arrays Forward Phase Antibody Microarrays NanoString Each microarray platform enables rapid and robust quantification of biomarkers at transcriptomic and post-translational pathway levels across multiple sample sets. Study size can be scaled to the needs of the experiment. People Professor Neil Carragher Academic Lead Alison Munro Facility Manager Camilla Drake Research Technician Our facilities are available to all within the University of Edinburgh, and also to external groups through funded collaboration or fee-for-service contract.
